WO2025096405 - METHODS OF TREATING BLOOD CANCERS
National phase entry is expected:
Publication Number
WO/2025/096405
Publication Date
08.05.2025
International Application No.
PCT/US2024/053363
International Filing Date
29.10.2024
Title **
[English]
METHODS OF TREATING BLOOD CANCERS
[French]
MÉTHODES DE TRAITEMENT DE CANCERS DU SANG
Applicants **
DANA-FARBER CANCER INSTITUTE, INC.
Inventors
LANE, Andrew A.
LUO, Qingyu
Priority Data
63/594,972
01.11.2023
US
63/651,456
24.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2891 | |
| EPO | Filing, Examination, Granting | 18237 | |
| Japan | Filing, Examination, Granting | 2483 | |
| South Korea | Filing, Examination, Granting | 2660 | |
| USA | Filing, Examination, Granting | 7510 |
Total:
33,781
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A method of treating a blood cancer comprising the administration of therapeutically effective amounts of a phosphatidylinositol 3-kinase gamma (PI3Kg) inhibitor and an antimetabolite, optionally also a therapeutically effective amount of a BCL-2 inhibitor, to a patient in need thereof. A method of identifying a blood cancer patient susceptible to treatment with a PI3Kg inhibitor. A method of treating a blood cancer comprising administration of a therapeutically effective amount of a p-21-activated kinase 1 (PAK-1) inhibitor, optionally also a therapeutically effective amount of a BCL-2 inhibitor, to a patient in need thereof.[French]
L'invention concerne une méthode de traitement d'un cancer du sang, comprenant l'administration de quantités thérapeutiquement efficaces d'un inhibiteur de phosphatidylinositol 3-kinase gamma (PI3Kg) et d'un antimétabolite, éventuellement également d'une quantité thérapeutiquement efficace d'un inhibiteur de BCL-2, à un patient qui en a besoin. L'invention concerne également une méthode d'identification d'un patient atteint d'un cancer du sang sensible à un traitement avec un inhibiteur de PI3Kg. L'invention concerne également une méthode de traitement d'un cancer du sang, comprenant l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de kinase 1 activée par p21 (PAK-1), éventuellement également d'une quantité thérapeutiquement efficace d'un inhibiteur de BCL-2, à un patient qui en a besoin.